Stock 3692 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 01:39:00 03/05/2024 pm IST 		5-day change 1st Jan Change
18.24 HKD +0.33% Intraday chart for Hansoh Pharmaceutical Group Company Limited +5.92% +15.74%
30/04 Hansoh Pharmaceutical’s 2023 Profit Up 27% MT
29/04 Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,33,984 1,87,313 91,686 77,600 84,854 1,00,089 - -
Enterprise Value (EV) 1 1,22,171 1,73,688 76,984 59,985 64,732 78,640 76,829 70,878
P/E ratio 51.7 x 71.9 x 35.2 x 29.8 x 26 x 26.3 x 26.5 x 22.5 x
Yield - 0.21% 0.47% 0.76% 1.49% 0.92% 0.94% 0.91%
Capitalization / Revenue 15.4 x 21.6 x 9.23 x 8.27 x 8.4 x 8.47 x 8.02 x 7.24 x
EV / Revenue 14.1 x 20 x 7.75 x 6.39 x 6.41 x 6.65 x 6.16 x 5.13 x
EV / EBITDA 40.9 x 57.7 x 24.2 x 19.9 x 20.9 x 18.7 x 18 x 14 x
EV / FCF 44.5 x 180 x 36.6 x 24.3 x 23.5 x 22.2 x 19.6 x 16.9 x
FCF Yield 2.25% 0.55% 2.73% 4.12% 4.25% 4.5% 5.09% 5.91%
Price to Book 10.3 x 10.5 x 4.58 x 3.43 x 3.29 x 3.5 x 3.19 x 2.8 x
Nbr of stocks (in thousands) 57,88,611 59,18,991 59,22,350 59,20,764 59,23,735 59,23,035 - -
Reference price 2 23.15 31.65 15.48 13.11 14.32 16.90 16.90 16.90
Announcement Date 30/03/20 30/03/21 29/03/22 27/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 8,683 8,690 9,935 9,382 10,104 11,818 12,480 13,825
EBITDA 1 2,990 3,008 3,175 3,019 3,101 4,198 4,274 5,071
EBIT 1 2,788 2,775 2,897 2,674 2,735 3,811 3,865 4,513
Operating Margin 32.11% 31.93% 29.16% 28.5% 27.07% 32.24% 30.97% 32.64%
Earnings before Tax (EBT) 1 3,001 3,098 3,300 2,948 3,766 4,325 4,428 5,217
Net income 1 2,557 2,569 2,713 2,584 3,278 3,742 3,753 4,509
Net margin 29.45% 29.56% 27.31% 27.54% 32.44% 31.67% 30.07% 32.62%
EPS 2 0.4481 0.4400 0.4400 0.4400 0.5500 0.6427 0.6375 0.7524
Free Cash Flow 1 2,748 962.8 2,102 2,470 2,754 3,539 3,912 4,189
FCF margin 31.65% 11.08% 21.16% 26.33% 27.26% 29.94% 31.35% 30.3%
FCF Conversion (EBITDA) 91.91% 32.01% 66.2% 81.83% 88.8% 84.29% 91.53% 82.61%
FCF Conversion (Net income) 107.49% 37.48% 77.48% 95.62% 84.03% 94.56% 104.24% 92.9%
Dividend per Share 2 - 0.0651 0.0732 0.1000 0.2129 0.1547 0.1594 0.1532
Announcement Date 30/03/20 30/03/21 29/03/22 27/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 4,083 3,980 4,711 4,402 5,534 4,434 4,948 4,511 5,593 6,186 5,718 5,485 6,682
EBITDA - - - - - - - - - - - - -
EBIT 1 - - - 1,337 1,560 1,322 1,353 1,047 1,688 2,074 1,118 1,520 1,049
Operating Margin - - - 30.38% 28.19% 29.8% 27.34% 23.2% 30.19% 33.54% 19.55% 27.72% 15.7%
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS - - - - - - 0.2200 - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 30/03/20 17/09/20 30/03/21 26/08/21 29/03/22 26/08/22 27/03/23 28/09/23 26/03/24 - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 11,812 13,625 14,702 17,615 20,122 21,449 23,260 29,210
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,748 963 2,102 2,470 2,754 3,539 3,912 4,189
ROE (net income / shareholders' equity) 33% 16.6% 14.3% 12.1% 13.5% 13.5% 12.5% 12.8%
ROA (Net income/ Total Assets) 18.3% 12.7% 11.3% 9.04% 10.4% 11% 10.7% 11.1%
Assets 1 14,002 20,184 23,976 28,581 31,521 34,109 35,186 40,696
Book Value Per Share 2 2.250 3.020 3.380 3.820 4.350 4.820 5.300 6.040
Cash Flow per Share 2 0.6100 0.4100 0.4300 0.4600 0.5200 0.6600 0.6500 0.8500
Capex 1 581 1,428 460 271 363 478 463 439
Capex / Sales 6.7% 16.43% 4.63% 2.89% 3.59% 4.04% 3.71% 3.17%
Announcement Date 30/03/20 30/03/21 29/03/22 27/03/23 26/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
16.9 CNY
Average target price
17.51 CNY
Spread / Average Target
+3.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED Stock Hansoh Pharmaceutical Group Company Limited
+15.74% 13.83B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. Financials Hansoh Pharmaceutical Group Company Limited